Benign Breast Disease and Breast Cancer Risk: Morphology and Beyond
暂无分享,去创建一个
[1] D. Barnes,et al. Cyclin D1 and associated proteins in mammary ductal carcinoma in situ and atypical ductal hyperplasia , 1998, The Journal of pathology.
[2] C. Bodian,et al. Use of keratin 35betaE12 as an adjunct in the diagnosis of mammary intraepithelial neoplasia-ductal type--benign and malignant intraductal proliferations. , 1999, The American journal of surgical pathology.
[3] A. Miller,et al. Immunohistochemical detection of c-erbB-2 and p53 in benign breast disease and breast cancer risk. , 1998, Journal of the National Cancer Institute.
[4] L. Brinton,et al. Breast cancer risk associated with proliferative breast disease and atypical hyperplasia , 1993, Cancer.
[5] R. Lattes,et al. Reproducibility and validity of pathologi classifications of benign breast disease and implications for clinical applications , 1993, Cancer.
[6] M. Merino,et al. Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions , 1995, Nature Medicine.
[7] W. Dupont,et al. Atypical hyperplastic lesions of the female breast: A long-term follow-up study , 1986 .
[8] R. Hutter. Goodbye to "fibrocystic disease". , 1985, The New England journal of medicine.
[9] D. Kodlin,et al. Chronic mastopathy and breast cancer: A Follow‐Up Study , 1977, Cancer.
[10] G. Colditz,et al. Biopsy confirmed benign breast disease, postmenopausal use of exogenous female hormones, and breast carcinoma risk , 2000, Cancer.
[11] W. Dupont,et al. Relative risk of breast cancer varies with time since diagnosis of atypical hyperplasia. , 1989, Human pathology.
[12] M. Meguid,et al. Estrogen receptor expression in benign breast epithelium and breast cancer risk. , 1998, Journal of the National Cancer Institute.
[13] L. Melton,et al. HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] C. Bodian,et al. Prognostic significance of benign proliferative breast disease , 1993, Cancer.
[15] S. Love,et al. Fibrocystic Disease of the Breast — A Nondisease? , 1982 .
[16] S. Bianchi,et al. Benign breast disease and breast cancer: A case‐control study in a cohort in italy , 1991, International journal of cancer.
[17] D. Henson,et al. Benign breast changes and the risk for subsequent breast cancer: an update of the 1985 consensus statement. Cancer Committee of the College of American Pathologists. , 1998, Archives of pathology & laboratory medicine.
[18] R. Mansel,et al. ABERRATIONS OF NORMAL DEVELOPMENT AND INVOLUTION (ANDI): A NEW PERSPECTIVE ON PATHOGENESIS AND NOMENCLATURE OF BENIGN BREAST DISORDERS , 1987, The Lancet.
[19] P. Wingo,et al. Histologic types of benign breast disease and the risk for breast cancer , 1992, Cancer.
[20] P. Taylor,et al. A prospective study of the development of breast cancer in 16,692 women with benign breast disease. , 1988, American journal of epidemiology.
[21] G. Colditz,et al. Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[22] S. Love,et al. Sounding board. Fibrocystic "disease" of the breast--a nondisease? , 1982, The New England journal of medicine.
[23] Simpson,et al. Loss of expression of transforming growth factor beta type II receptor correlates with high tumour grade in human breast in‐situ and invasive carcinomas , 2000, Histopathology.
[24] R. Laucirica,et al. p53 accumulation in benign breast biopsy specimens. , 1995, Human pathology.
[25] W D Plummer,et al. Understanding the relationship between relative and absolute risk , 1996, Cancer.
[26] J. Rosai,et al. Borderline Epithelial Lesions of the Breast , 1991, The American journal of surgical pathology.
[27] R. Millikan,et al. p53 mutations in benign breast tissue. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] C. Paúl,et al. Education, leisure activities and cognitive and functional ability of Alzheimer's disease patients: A follow-up study , 2013, Dementia & neuropsychologia.
[29] R. Sutherland,et al. Cyclin D1 protein is overexpressed in hyperplasia and intraductal carcinoma of the breast. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[30] W. Dupont,et al. Influence of exogenous estrogens, proliferative breast disease, and other variables on breast cancer risk , 1989, Cancer.
[32] S J London,et al. A prospective study of benign breast disease and the risk of breast cancer. , 1992, JAMA.
[33] W D Dupont,et al. Risk factors for breast cancer in women with proliferative breast disease. , 1985, The New England journal of medicine.
[34] A. Zetterberg,et al. Immunohistochemical expression of the mutant p53 protein and nuclear DNA content during the transition from benign to malignant breast disease. , 1994, Human pathology.
[35] David L. Page,et al. Anatomic indicators (histologic and cytologic) of increased breast cancer risk , 1993, Breast Cancer Research and Treatment.
[36] R. Hiatt,et al. Risk of breast cancer after benign breast diseases. Variation by histologic type, degree of atypia, age at biopsy, and length of follow-up. , 1992, American journal of epidemiology.
[37] D. Weiner,et al. Immunohistochemical evaluation of c-erbB-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast. , 1990, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[38] N. Ordóñez,et al. Extranodal Follicular Dendritic Cell Sarcoma of the Head and Neck Region: Three New Cases, with a Review of the Literature , 2002, Modern Pathology.
[39] D. Page,et al. Combined histologic and cytologic criteria for the diagnosis of mammary atypical ductal hyperplasia. , 1992, Human pathology.
[40] A. Bankfalvi,et al. Cytokeratin 5/6 immunohistochemistry assists the differential diagnosis of atypical proliferations of the breast , 2000, Histopathology.
[41] G. Colditz,et al. Radial scars in benign breast-biopsy specimens and the risk of breast cancer. , 1999, The New England journal of medicine.
[42] Julian Peto,et al. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer , 1997, The Lancet.
[43] S J Schnitt,et al. Interobserver Reproducibility in the Diagnosis of Ductal Proliferative Breast Lesions Using Standardized Criteria , 1992, The American journal of surgical pathology.
[44] J. Sloane,et al. Histopathologic Types of Benign Breast Lesions and the Risk of Breast Cancer: Case–Control Study , 2002, The American journal of surgical pathology.
[45] G. Colditz,et al. Pathologic features of breast cancers in women with previous benign breast disease. , 2001, American journal of clinical pathology.
[46] W. Dupont,et al. Ductal involvement by cells of atypical lobular hyperplasia in the breast: a long-term follow-up study of cancer risk. , 1988, Human pathology.
[47] S. Heffelfinger,et al. Vascularity of proliferative breast disease and carcinoma in situ correlates with histological features. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[48] J. Bahi,et al. Angiogenesis and risk of breast cancer in women with fibrocystic disease. , 1994, Journal of the National Cancer Institute.
[49] N. Sneige,et al. Molecular and Biologic Markers of Premalignant Lesions of Human Breast , 2002, Advances in anatomic pathology.
[50] F. Tavassoli,et al. A comparison of the results of long‐term follow‐up for atypical intraductal hyperplasia and intraductal hyperplasia of the breast , 1990, Cancer.